A research team led by scientists from the Karolinska Institute and Danderyd Hospital in Sweden report that high levels of mucosal antibodies in the airways reduce the risk of being infected by omicron. However, many people do not receive detectable antibodies in the airways despite three doses of the SARS-CoV-2 vaccine, add the researchers.
Their study “Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection” is published in the New England Journal of Medicine.
The COMMUNITY study enrolled 2,149 health care workers in the spring of 2020 at Danderyd Hospital, Sweden. Study participants and their immune responses against the coronavirus SARS-CoV-2 are since then followed up every four months. A sub-study between January and February 2022 screened 338 triple-vaccinated healthcare workers for SARS-CoV-2 infection. Antibody levels in blood and airways were determined at the start of the screening period, and one in six (57 participants) was subsequently infected with omicron during the four-week screening period. This allowed the research group to investigate immunity against omicron breakthrough infection as well as immune boosting following breakthrough infection.
The levels of mucosal IgA antibodies (immunoglobulin A) were measured in the airways because they play an important role in the protection against respiratory infections. All participants had high levels of systemic antibodies (e.g. in the blood) after three doses of the vaccine, but only 62 per cent had detectable mucosal airway antibodies (e.g., in the nose). High levels of mucosal airway antibodies more than halved the risk of becoming infected with omicron.
“Taken together, these findings suggest that wild-type SARS-CoV-2 spike-specific mucosal IgA is protective against omicron infection. Further studies are warranted to determine whether vaccines that induce a combination of mucosal and systemic immune responses would confer stronger protection than intramuscular vaccines,” write the investigators.
“It is not surprising that antibodies in the respiratory tract neutralize the virus locally, but these findings show, for the first time, that SARS-CoV-2 mucosal antibodies in the airways actually protect against omicron infection,” says lead author Charlotte Thålin, MD, and associate professor at the Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute.
High mucosal antibodies in the airways were also associated with a lower viral replication among those infected with omicron. After omicron infection, a 40-fold increase in mucosal airway antibodies was found in the majority of participants, even if the infection had been mild.
The researchers also showed that participants with SARS-CoV-2 infection prior to vaccination had significantly higher levels of mucosal airway antibodies after vaccination compared with triple-vaccinated with no prior SARS-CoV-2 infection. This may explain why so-called hybrid immunity, the combination of infection and vaccine, provides stronger protection against infection than just vaccines.
“We are now in a situation with omicron infecting people despite having received several doses of today’s intramuscular vaccines,” notes Thålin. “It is tempting to think that a vaccine administered through the nose or mouth, where SARS-CoV-2 enters the body, could provoke a local immune response preventing infection at an earlier stage. Several vaccines in the form of a nasal spray are now being investigated in clinical trials with the hope of being able to reduce the spread of infection and thus reduce the risk of developing new virus variants.”